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Objectives.Theprimaryobjectiveofthisstudywastodeterminetherelationshipbetweenwaist-to-hipratio(WHR),cardiovascular
(CV) events, and mortality in peritoneal dialysis (PD) patients. A secondary objective was to investigate the association between
abdominal obesity and systemic inﬂammatory markers. Methods. This is a prospective study of 22 prevalent PD patients. WHR
was measured at baseline. C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were measured.
Main outcomes were ﬁrst CV event and death from all causes. Survival analysis was used to examine the relationship between
anthropomorphicmeasuresandclinicaloutcomes.Results.Meanfollow-upperiodwas3.1years.InKaplan-Meieranalysis,survival
was lower in those with higher WHR (P = .002). In Cox regression, WHR independently predicted mortality and ﬁrst CV event
after adjustment for known ischemic heart disease (hazard ratio [HR] 1.17, conﬁdence interval [CI] 1.05–1.30 for death; HR
1.13, CI 1.01–1.26 for CV event). WHR correlated with serum TNF-α (r = 0.45; P = .05). Conclusion. The results of this study
suggest WHR may be a risk factor for increased CV events and mortality in PD patients. Abdominal obesity is also associated with
inﬂammatory markers. Larger studies are warranted to conﬁrm these ﬁndings.
1.Introduction
Cardiovascular (CV) disease is the leading cause of death in
dialysis patients [1]. Obesity increases the risk of CV disease
in the general population [2]. In particular, abdominal obe-
sity as measured by waist-to-hip ratio (WHR) has emerged
as a better predictor of CV risk than body mass index (BMI)
[3]. In several large epidemiologic studies, WHR was an
independent predictor of coronary artery disease and death
[3–5].
Studies on abdominal obesity in patients with chronic
kidney disease are limited. In one study of patients with
mild to moderate chronic kidney disease (CKD), increased
WHR predicted fatal and nonfatal coronary artery disease
events [6]. The ﬁrst study of WHR in hemodialysis (HD)
patients was recently published in [7]. Higher WHR and
waist circumference (WC) predicted CV and all-cause
death after adjusting for BMI whereas higher BMI was
protective [7]. To our knowledge, there are no studies
in peritoneal dialysis (PD) patients that have assessed the
relationship between WHR and clinically important adverse
events.
One of the postulated mechanisms for abdominal obe-
sity’s detrimental eﬀect is its relationship with inﬂammatory
markers, and inﬂammation is associated with increased CV
risk in chronic kidney disease [8, 9]. Excess abdominal fat
has been shown to be associated with increased C-reactive
protein (CRP), tumor necrosis factor-alpha (TNF-α), and
interleukin-6 (IL-6) in general populations [10, 11], but
studies in PD patients are scarce [12].
T h ep r i m a r yo b j e c t i v eo ft h i ss t u d yw a st oi n v e s t i g a t e
the relationship between central obesity as measured by
WHR, and CV events and death in PD patients. A secondary
objective was to determine if there was an association
between anthropomorphic measures and systemic inﬂam-
matory markers.2 International Journal of Nephrology
2. Methods
This is a prospective study of 22 prevalent, stable, and
consenting PD patients who were recruited from one of
the aﬃliate teaching hospitals associated with McMaster
University, (St. Joseph’s Healthcare), Hamilton, Canada.
Study protocol was approved by the St. Joseph’s Healthcare
Research Ethics Board. Patients were included in the study if
they were 18 years of age or older and on PD for at least 3
months. Exclusion criteria included a history of peritonitis
in the previous month and inability to provide informed
consent.
Patient charts were reviewed to collect demographic
information, a list of comorbidities, medications, and dial-
ysis prescription. Transport property of the peritoneal mem-
brane was determined by the fast peritoneal equilibration
test [13], and transport status was established based on the
four-hour dialysate/plasma (d/p) creatinine. Residual renal
function was calculated as the mean of 24-hour urea and
creatinine clearances.
On the day of testing, two hours into the dwell for the
peritoneal equilibration test, serum IL-6, TNF-α, and CRP
(Cardiophase∗ hsCRPDadeBehringInc.Newark,DE)levels
were drawn. IL-6 and TNF-α were measured by ELISA (R&D
Systems, Minneapolis MN).
Weight and height were measured without shoes. Mea-
surements and patient assessment were completed after
patients had drained their overnight dialysate dwell. Waist
circumference (WC) was measured around the narrowest
point between the coastal margin and the iliac crest. Hip
circumference was measured at the level of the widest
diameter around the gluteal region. Waist-to-hip ratio is
waist circumference divided by hip circumference. BMI is
weight divided by (height)2.
Patients were recruited between March and September of
2005. TheywerefolloweduntilDecember2008ordeath.The
main outcomes were ﬁrst CV event (myocardial infarction
[MI], stroke, amputation, cardiac revascularization, or CV
death); only one event was included for the analysis and
death from all causes. MI was diagnosed when two out of
three of the following criteria were met: typical symptoms,
elevation in cardiac enzyme (troponin T > 0.1mcg/L), or
diagnostic changes on the electrocardiogram. Stroke was
deﬁned as new neurologic deﬁcit thought to be vascular in
origin and lasting more than 24 hours. CV death included
death caused by MI, stroke, complications of peripheral
arterial disease, and all sudden death.
3. Statistics
All analyses were performed with the statistical package,
SPSS (version 17; SPSS Inc. Chicago, IL). Subjects were
divided in to two groups according to the median value
for their gender for each anthropomorphic measure. Mann-
Whitney U test was used to compare continuous base-
line variables between groups. Fisher exact test was used
to compare categorical CV risk factors between groups.
Bivariate correlations are reported using the Spearman rank
correlation coeﬃcient.Two-sidedprobability(P)valuesw er e
Table 1: Baseline characteristics of the 22 peritoneal dialysis
patients enrolled.
Variable
PD Patients N = 22
n (%) or Mean
(Standard Deviation)
Age (years) 61 (SD 15.6)
Male 13 (59%)
Caucasian 21 (95%)
Time on dialysis (years) 2.1 (SD 2.8)
Diabetes Mellitus 8 (37%)
Ischemic heart disease 5 (23%)
Peripheral arterial disease 3 (14%)
Hypertension 18 (82%)
Any history of smoking 11 (50%)
Waist Circumference (cm) 101 (SD 11.5)
Men 104 (SD 12.6)
Women 97.1 (SD 8.85)
Waist-to-Hip Ratio 0.98 (SD 0.09)
Men 1.01 (SD 0.08)
Women 0.94 (SD 0.09)
BMI (kg/m2) 27.7 (SD 4.94)
Men 28.2 (SD 5.14)
Women 27.1 (SD 4.87)
calculated with statistical signiﬁcance set at alpha ≤.05.
Univariate comparisons of survival between those with high
or low WHR were performed with Kaplan-Meier analysis
andlog-ranktests.TherelationshipsbetweenWHRandclin-
ical outcomes were also investigated using Cox regression.
Logistic regressionwasusedifassumptionofproportionality
was violated. Baseline variables found to be signiﬁcantly
diﬀerent between high and low WHR groups were entered
into a Cox regression model as covariate. However, the
number of variables entering the model was limited by the
number of events to ensure model stability [14].
4. Results
All 43 eligible patients at our centre were approached, and
22 patients consented. The majority of the patients declined
due to time commitment and need for followup. All enrolled
patients were followed to the end of the study.
Baselinecharacteristicsofthe22patientsaresummarized
in Table 1.M e a na g e± standard deviation was 61 ± 16 years;
59% were men, and 95% were Caucasian. At baseline, 37%
had diabetes (DM), and 23% had known ischemic heart
disease (IHD). Median WHR was 1.01 for men and 0.95 for
women.
After a mean follow-up period of 3.1 ± 0.81 years, 9
patients(41%)hadatleastoneCVevent.Therewere9deaths
(41%mortality),and5outofthe9deathswererelatedtoCV
causes (3 cardiac events, 1 stroke, and 1 ruptured abdominal
aortic aneurysm). 4 out 5 CV deaths occurred in those with
WHR above the gender-speciﬁc median. The other 4 deathsInternational Journal of Nephrology 3
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Figure 1: Kaplan-Meier survival curves for patients above and
below the gender-speciﬁc median for WHR.
were due to infection or malignancy (2 with high WHR and
2withlowWHR).Therewere9ﬁrstCVevents;6occurredin
those with high WHR (5 MIs and 1 stroke), and 3 occurred
in those with low WHR (all MIs).
CV risk factors and other baseline characteristics with
knownprognosticsigniﬁcanceinPDpatientswerecompared
between the two groups of patients with WHR above and
below the gender-speciﬁc medians. There were no signiﬁcant
diﬀerences in median age (61 and 62; P = .74), male gender
(67% and 54%; P = .67), the presence of hypertension
(89% and 77%; P = .62), DM (56% and 23%; P = .19),
any smoking history (67% and 54%; P = .67), known IHD
(44% and 15%; P = .18), median albumin (38 and 36g/L;
P = .90), peritoneal transport characteristics (high or high
average 100% and 77%, P = .24), residual renal function
(4.36 and 4.65mL/min; P = .79), and transfer to HD (22
and 15%; P = 1.0). There were also no diﬀerences in PD
modality (automated versus continuous ambulatory PD),
(P = .41) use of icodextrin, (P = .36), or peritonitis rates
(P = 1.0).
Kaplan-Meier survival analysis showed a lower cumula-
tivesurvival(P = .002)inthosewithhigherWHR(Figure 1).
There were also increased overall CV events (P = .03) and
CV deaths (P = .01) in the group with higher WHR. Kaplan-
Meier survival analysis was not performed for WC and BMI
due to violation of the assumption of proportionality.
Using Cox regression, the hazard ratio (HR) for death
withevery0.01changeinWHRwas1.15(conﬁdenceinterval
[CI] 1.05–1.24), and for ﬁrst CV event, the HR was 1.13
(CI1.03–1.25).Noneofthemeasuredbaselinecharacteristics
were signiﬁcantly diﬀerent between high and low WHR
groups. However, because of a trend towards increased IHD
Table 2: Correlations between systemic inﬂammatory markers and
anthropomorphic measures.
Waist-to-Hip
ratio
r (P)
Waist
circumference
r (P)
Body mass index
r (P)
Inﬂammatory
markers
CRP NS 0.45 (P = .04) NS
TNF-α 0.45 (P = .05) 0.58 (P = .007) NS
IL-6 NS NS NS
r: correlation coeﬃcient, CRP: C-reactive protein, TNF-α: tumor necrosis
factor-α, IL-6: interleukin-6, and NS: nonsigniﬁcant.
and DM in the high WHR group and the known association
with poor outcomes in dialysis patients, IHD and DM
were entered as covariates in Cox regression models. After
adjustingforIHD,HRfordeathwas1.17(CI1.05–1.30),and
HRforﬁrstCVeventwas1.13(CI1.01–1.26)inpatientswith
high WHR. After adjusting for DM, high WHR patients had
a HR for death equal to 1.16 (CI 1.05–1.28), and HR for ﬁrst
CV event was 1.12 (CI 1.01–1.24).
Using logistic regression, neither WC nor BMI predicted
death (odds ratio [OR} 1.06 CI 0.97–1.16 for WC and OR
1.03 CI 0.86–1.22 for BMI, resp.) or CV events (OR 1.07 CI
0.98–1.17 for WC and OR 1.06 CI 0.89–1.26 for BMI, resp.).
WHR correlated with TNF-α but not with CRP or IL-
6( Table 2). WC correlated with TNF-α and CRP. BMI
did not correlate with measured inﬂammatory markers.
No signiﬁcant correlations were found between serum
inﬂammatory markers and DM, known IHD, cholesterol
proﬁle, or peritoneal membrane transport characteristics.
5. Discussion
The main ﬁnding of this study is that increased WHR is
associated with increased CV events and all-cause mortality
in PD patients. To our knowledge, this is the ﬁrst report
of such a relationship in PD patients. These results are
consistent with what has previously been identiﬁed in the
general population in [4], in patients with CKD in [6],
and those on HD in [7]. Our data is also consistent with
results showing that abdominal obesity is a stronger adverse
prognosticator than BMI and that WHR may be a better
measurement of abdominal adiposity than WC [3, 6]. In the
INTERHEART study, BMI showed the weakest association
with myocardial infarction whereas waist circumference was
intermediate between WHR and BMI [3]. In HD patients,
WC was a signiﬁcant predictor of CV and all-cause mortality
only after adjustment for BMI whereas WHR was predictive
of mortality both before and after adjustment for BMI [7].
Although there was a high mortality rate of 41% during a
mean follow-up period of 3.1 years in our study, this result
is in keeping with the known morality rate of the Canadian
dialysis population [15, 16].
Inthegeneralpopulation, higherBMIpredictsmortality,
but the relationship appears to diﬀer for patients on dialysis
[17]. Studies in HD patients have shown paradoxically4 International Journal of Nephrology
increased survival with higher BMI [17], but results in
PD patients are mixed [18]. In our study, there was no
association between increased BMI and clinical outcomes.
This neutral relationship was also found in several other
studies in PD patients [18, 19]. Some have postulated
that protective eﬀects of elevated BMI may be neutralized
by increased PD-related infection, underdialysis, or more
rapid loss of residual renal function [20]. The conﬂicting
ﬁndings may also be in part related to the inability of
BMI to diﬀerentiate between fat, muscle tissue, and water.
BMI reﬂects a combination of multiple factors including
subcutaneous fat, visceral fat, muscle mass, and nutritional
and hydration status [21]; these factors may have mixed and
competing eﬀects on survival [22]. Therefore, BMI does not
seem to be a reliable prognostic factor in PD patients. On
the other hand, WHR is primarily a measure of visceral fat
which is thought to be particularly detrimental due to its
proatherogenic and proinﬂammatory properties [10].
In this study, increased WHR is associated with higher
levels of TNF-α, and increased WC is associated with both
higher levels of TNF-α and CRP. These correlations are
consistent with the existing hypothesis that visceral fat has
important inﬂammatory properties. Studies in the general
population have shown higher circulating levels of CRP,
TNF-α, and IL-6 in those with increased abdominal fat when
compared with BMI-matched controls [10, 23]. In one small
study of PD patients, WHR was signiﬁcantly associated with
IL-6butnotwithCRP,orTNF-α[12].However,factorsother
than abdominal obesity such as chronic infections, volume
overload, accumulation of advanced glycation end-products,
and peritoneal membrane inﬂammation can potentially
contribute to systemic inﬂammation in PD [24]. These
factorsmayexplaindiﬀerencesinresultsbetweenstudiesand
the lack of association between WHR and CRP or IL-6 in our
study.
When using gender-speciﬁc cutoﬀs for abdominal obe-
sity deﬁned by WC [25], the prevalence of abdominal obesity
in this study (64%) is higher compared with that previously
reported in HD patients (39%) in [7]. The mean WHR (0.98
± 0.09) in our cohort was also higher than that reported
in HD patients (0.93 ± 0.10) [7]. PD patients may be
at higher risk of developing abdominal obesity compared
with HD patients because of the use of glucose-based
dialysis solutions. Glucose loading in PD has been postulated
to contribute to hyperinsulinemia and insulin resistance
[26, 27]; these factors are in turn highly associated with
abdominal obesity [11, 28]. In one study, patients developed
a23%increaseinintra-abdominalfatareaafterinitiatingPD,
despite a lack of signiﬁcant increase in weight or proportion
of total fat mass [29]. Abdominal obesity may therefore
be a particularly important consideration in PD patients,
and this highlights the importance of clinical evaluation of
glucose sparing PD prescriptions [30]. Randomized trials of
glucose-sparing strategies using new dialysate solutions are
underway.
Thestrengthofthisstudyistheprospectivedesign,longi-
tudinal followup, and completeness of followup(100%). The
main limitation of this study is the small sample size, which
precludes extensive multivariate analysis. After adjusting for
IHD and DM, WHR remained an independent risk factor
for mortality and ﬁrst CV event. Although there was no
diﬀerence in the presence of other major CV risk factors
(age, gender, diabetes, hypertension, and smoking history)
orknownadverseprognosticvariablesinPDpatients(serum
albumin, peritoneal transport characteristics, and residual
renal function) between patients with high or low WHR,
it is possible that signiﬁcant diﬀerences were not detected
due to the small sample size. It may be that WHR is
associated with a number of other risk factors however
adjustment for additional potential confounding factors in
the Cox regression model was also not possible with the
small sample size [14]. This study should therefore be
regarded as hypothesis-generating, and the preliminary data
presented here provides justiﬁcation for larger studies in the
future.
In conclusion, this small study suggests increased WHR
may be a risk factor for CV events and mortality in PD
patients.WHRisasimplemeasurementthatcanbeincorpo-
rated in clinical practice, and larger studies with multivariate
analysis are warranted to conﬁrm the relationship between
WHR and clinical outcomes in PD patients.
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